CEO Stephane Bancel said the letter refusing review did not cite 'any safety or efficacy concerns'.

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.

CEO Stephane Bancel said the letter refusing review did not cite 'any safety or efficacy concerns'.